Send to

Choose Destination
See comment in PubMed Commons below
Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Collaborators (201)

Abramsky O, Achiron A, Agius M, Aichner F, Altenkirch H, Amato MP, Anten B, Arbizu T, Ash P, Ballario C, Bashir K, Baum K, Baumhackl U, Beaver G, Belova A, Berger J, Berger T, Berlit P, Beuche W, Bhan V, Bigley K, Bissay V, Blake C, Bö L, Boyko A, Brochet B, Brown M, Callegaro D, Carra A, Carroll W, Cascione M, Christie S, Clanet M, Clavelou P, Clementino VI, Confavreux C, Cooper J, Cree B, Cross A, Csanyi A, Czlonkowska A, D'Hooghe M, Damier P, Debouverie M, Defer G, Demina T, Deri N, Diem R, Dressel A, Dubois B, Dunne P, Duquette P, Durelli L, Edan G, Elias S, Elovaara I, Esfahani F, Evtushenko S, Fabijan TH, Fernández O, Ferreira ML, Fink A, Flechter S, Ford C, Francesconi C, Freedman M, Fryze W, Gabbai A, Gács G, Gallo P, Gazda S, Gerloff C, Glyman S, Goodman A, Gottesman M, Grand'Maison F, Guarnaccia J, Gutierrez A, Haas J, Hansen HJ, Hardiman O, Heard R, Heidenreich F, Herbert J, Herminia Scola R, Hodgkinson S, Hoffmann F, Holub R, Huddlestone J, Hughes B, Hughes M, Hunter S, Hurwitz B, Izquierdo G, Jacobasch E, Jacques F, Jakab G, Jongen P, Karageorgiou C, Karni A, Kasper L, Kaufman M, Keidel M, Khatri B, Kiefer R, Kirzinger S, Kita M, Komoly S, Kotov S, Kozubski W, Kumlien E, Kwiecinski H, Labouge P, LaGanke C, Lapierre Y, Lebrun-Frenay C, Leist T, Leon SA, Luetic G, Lynch S, Lynch T, Malkova N, Maltezou M, Markowitz C, Martin C, Mattle H, Mattson D, Metra M, Meyding-Lamadé U, Milo R, Milonas I, Miller A, Miller T, Minagar A, Mitchell G, Moreau T, Mosberg R, Murphy R, Nehrych T, Nikl J, Odinak M, Oschmann P, Owen King J, Pagani L, Pereira Damasceno B, Podemski R, Pöhlau D, Pozzilli C, Rammohan K, Reunanen M, Rice G, Richardson P, Rivera V, Rizvi S, Rogozhyn V, Rolak L, Rosenkranz T, Rotta R, Sanders E, Sater R, Satgur Gupta A, Schwartz R, Sedal L, Sega-Jazbec S, Selchen D, Selmaj K, Sheremata W, Shvets T, Silver D, Simsarian J, Skoromets A, Smiroldo J, Sokolova L, Solovyova Y, Sommer N, Spirin N, Stangel M, Stark E, Steinbrecher A, Stemper B, Stolyarov I, Strasser-Fuchs S, Sweeney B, Tettenborn B, Thrower B, Tilbery CP, Traboulsee A, Trojano M, Tubridy N, Tyor W, Valikovics A, Vermersch P, Vollmer T, Voloshyna N, Vrech C, Wajgt A, Weller B, Wendt J, Yakhno N, Yeung M, Zavalishin I.

Author information

St Michael's Hospital, Toronto, Canada.

Erratum in

  • Lancet Neurol. 2011 Feb;10(2):115.
  • Lancet Neurol. 2009 Nov;8(11):981.
  • Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].



The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 microg or 500 microg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis.


Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 microg or 500 microg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2.0-3.5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502.


We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p<0.0001), whereas injection-site reactions were more common in patients treated with glatiramer acetate (p=0.0005). Patient attrition rates were 17% (153 of 888) on 250 microg interferon beta-1b, 26% (227 of 887) on 500 microg interferon beta-1b, and 21% (93 of 445) for glatiramer acetate.


500 microg interferon beta-1b was not more effective than the standard 250 microg dose, and both doses had similar clinical effects to glatiramer acetate. Although interferon beta-1b and glatiramer acetate had different adverse event profiles, the overall tolerability to both drugs was similar.


Bayer HealthCare Pharmaceuticals.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center